CTIX Discussion Topics 08/26/2014 06:32:23 $CTIX Yes, I

New Post Public Reply Private Reply Replies (0) Message Board
Jake13
CTIX Discussion Topics 08/26/2014 06:32:23 $CTIX
Yes, I would love Cellceutix to test the $21,5 mark today
Been a stockholder for over a year now, tempted to grow my investment...
Exciting times for the company (and us)!
Good morning Smitter. Hope everyone has a green Tuesday.

Around 9 trading days left until the CTIX presentation at R&R Conference.

CTIX Stock Message Board http://investorshangout.com/Cellceutix-Corpor...TIX-87375/

Good Morning, World Good Morning, CTIX!

Everyone have a great day! Let's test that $21.5-2.30 mark!
TOB, thanks for all the good posts and charts. Looks like we have a golden cross using the EMA.
Not quite yet with SMA.


Good comparative for Cellceutix with right news.

Quote:
A bit of biotech comparative here, at 3.30 Cellceutix will be market performing to par with Gilead Sciences since 2012. A very impressive goal for Leo and company to attain and maintain in my eyes.....................Try and explain TA for gild over 2 1/2 years time other than once at the weekly 50 dma, I sure can't, unless they defy gravity (i.e. fundamentals always rule the day) -etradeedge


News of the sort that is entirely possible for CTIX would indeed result in a chart which defied TA or gravity.

Amazing as the Gilead chart is for the last two years, who doesn't believe that with the right news CTIX could make a ~ 2 bagger from 3.30 in a similar period?

GILD Weekly, click to enlarge

A bit of biotech comparative here, at 3.30 Cellceutix will be market performing to par with Gilead Sciences since 2012. A very impressive goal for Leo and company to attain and maintain in my eyes.....................Try and explain TA for gild over 2 1/2 years time other than once at the weekly 50 dma, I sure can't, unless they defy gravity (i.e. fundamentals always rule the day).
It really is hard to believe CTIX has traded inside the December 2012 monthly candle for an amazing 21 months.


Quote:
Cellceutix is trying to break out of a 21 month (can you believe it) pennant formation as I believe JohnB first pointed out. A 1 x 1 measured move (if 2.40 can be taken out) is 3.40 first stop. Our very own Dr Rally 2.00 resistance is futile call just might turn out to be the last train to Clarksville and The Call of the year............. -etradeedge


CTIX Monthly, The Mother Of All Pennants! click to enlarge


Dr Rally Monkey says: "The CTIX train has left the station: Next Stop Clarksville"




Interesting... I guess just because Think or Swim is owned by TD Ameritrade, that doesn't mean they use the same price feed for CTIX OTC.

It seems so far only iHub and Think or Swim have today's CTIX volume pegged at 698,454, all these other brokers show the lower number.

Next step is to head straight to the source, OTC Markets CTIX Quote which also shows the lower number.



Rally Monkey, did you swipe the missing 79,145 CTIX shares?
And let's not forget TD's 1.60 line in the sand better buy it now call either when some others were calling for 1.40 and 1.20. It's time to give credit where credit is due. TD, am I out of the dog house for good yet?
Wild did you demand payment in CTIX shares?
Wild when they name a Board of Directors it will come as no surprise to see you as a Director along with BK, TP, and a few others lol.
Go CTIX !


It's worth it as long as those $$ go towards more CTIX shares. Go spreadsheets!
Way to go, Wild! Hopefully they coaxed you with an offer you couldn't refuse. Go CTIX!
Thanks for all the great posts and I'm missing all my CTIX Pals ! I apparently lost the only two brain cells I had left 3 weeks ago when I came out of retirement at 66 and accepted a job from an ex boss....crazy busy and no time.....but I STILL LOVE CTIX and it's Leadership and Potential ! I'm IN and ROOTING HEARTILY even if it is from 32K feet up in a plane ! CTIX IS ROCKING ! Thanks Leo and Dr. M ! Miss Y'all on the board ! Back to spreadsheets UGH !

GO CTIX !
From the May 27th PR:

Separately, Cellceutix recently presented its defensin mimetics and antimicrobials at the facilities of one of the world's largest pharmaceutical companies. Discussions are progressing towards a material transfer agreement as the pharma wishes to research the compounds for a variety of uses, although Cellceutix makes no assurances of a final agreement being reached.

THIS HAS TO BE RELATED TO THE 66lb ELEPHANT IN THE ROOM.

Thanks! Go CTIX!
Good point Sox. Let's hope for a little competition among big pharma to acquire or partner a piece of ctix assets.

TD you call it better than a Monday Night Football game!

Go CTIX!
Thanks, 58. I appreciate your comment. In all fairness, this was the call I made after Matagordville asked if I thought we would $2.10.


TheDane Monday, August 25, 2014 11:41:08 AM
Re: Matagordaville post# 66686
Scroll down for more posts ▼

Top 10 Most Recent News Articles

NetEase Miss Opens an Investigation, Not a Verdict

Updated Category News Views 132

A two-dollar earnings gap can make a shareholder base jumpy fast, and NetEase just handed the market a rough set of numbers to chew on. The November 19 notice says NetEase's third-quarter 2026 report missed Wall Street expectations on both earnings and revenue, followed by a sharp decline in the shares. That has prompted SueWallSt, powered by Levi & Korsinsky LLP, to...

Continue Reading
SEIA's Young Advisors Put Succession Plans to the Test

Updated Category News Views 15

A $166 million average book is not a cute training-program statistic. It says SEIA’s advisors aged 30 to 39 are already carrying serious client responsibility, and that matters because the registered investment advisory business is headed into a succession crunch nobody can solve with a glossy recruiting brochure. You Cannot Hand Off Trust Like a Spare Key Clients may...

Continue Reading
TOP-REAL Tests Digital Monitoring in HER2 Cancer Care

Updated Category News Views 116

A cancer treatment can be extraordinarily potent and still get derailed by what happens on an ordinary Tuesday at home. That unglamorous gap between clinic visits is the whole point of TOP-REAL, a phase II academic study presented at ESMO AI & Digital Oncology 2026. Solti and its European partners are testing whether closer digital follow-up can catch trouble early enough...

Continue Reading
Midea’s SC26 Cooling Pitch Targets AI Build Delays

Updated Category News Views 80

Heat is the uninvited partner in every AI build, and Midea is making a sensible argument that nobody gets paid for racks sitting idle while piping crews wrestle with a complicated cooling plant. At SC26 in Chicago, held November 17 through 19, the company made its North American debut for a modular prefabricated AI data-center cooling setup built around a magnetic coolant...

Continue Reading
UTI Faces Fresh Scrutiny After Its Earnings Guidance Miss

Updated Category News Views 113

A Guidance Gap That Cannot Be Shrugged Off A $0.20-per-share hole is a nasty thing to find after management said it could see the road ahead. Universal Technical Institute reported fiscal 2026 diluted earnings per share of $0.60, below the $0.71 to $0.80 range it reaffirmed on May 6. That is at least $0.11 under the low end and roughly 21% below the midpoint. For...

Continue Reading
YPTC’s Florida Office Bets on Nonprofit Finance Needs

Updated Category News Views 36

A Local Flag Planted After Years of Work Florida nonprofits do not need another consultant waving a glossy slide deck around; they need clean books, grant compliance, and somebody who can tell them where the cash is going before the lights start blinking red. That is the practical opening YPTC is chasing with a Jacksonville-based Florida office, its sixteenth office...

Continue Reading
Cleveland Picks Golden Key for Citywide Leadership Training

Updated Category News Views 215

A Citywide Bet on Better Management Municipal management rarely grabs headlines until something breaks, which is precisely why Cleveland's decision to bring in Golden Key Group deserves a closer look. Announced November 20, 2026, the arrangement calls for GKG to design and deliver a citywide management training program through Cleveland's Department of Personnel and Human...

Continue Reading
BioVersys AlpE Data Offers a Measured TB Treatment Signal

Updated Category News Views 119

Tuberculosis drug development rarely hands anybody a clean victory lap, and BioVersys' latest readout is no exception. The completed 14-day Phase 2a ENABLE study gives alpibectir plus ethionamide, known as AlpE, a credible early clinical signal in newly diagnosed drug-sensitive pulmonary TB. That matters. It does not, however, settle the far larger question of whether...

Continue Reading
Simmons Clarifies Texas Loan Exposure, But Risks Remain

Updated Category News Views 14

A $45 million discrepancy is not a rounding error, and Simmons First National has every reason to swat it down hard. The bank says recent reporting overstated financing tied to a Texas multifamily development at $133 million. Its stated total is roughly $88 million, with about $44 million participated to another financial institution. For shareholders in NASDAQ:SFNC, that...

Continue Reading
VIGGO’s Mix1Pro Tests Practical Commercial Cleaning

Updated Category News Views 61

A cleaning robot earns its keep in the ugly corners, not under convention-center lights. VIGGO used the ISSA Show North America gathering in Las Vegas, held November 17–19, 2026, to introduce the Mix1Pro, a compact commercial machine aimed at indoor facilities below 53,800 square feet. That target matters. Smaller, messier sites are where autonomy can look terrific on a...

Continue Reading

Top 5 Most Recently Viewed Articles

Enzyme Inhibitor Market Growth Forecast: US$ 5.9 Billion

Updated Category News Views 125

The Future of the Enzyme Inhibitor Market The enzyme inhibitor market is positioned for significant growth, projected to reach US$ 5.9 billion by 2034, following an estimated rise from US$ 2.8 billion in 2023. This impressive growth is driven by a compound annual growth rate (CAGR) of 7.1% over the next decade. Enzyme inhibitors, particularly angiotensin-converting enzyme...

Continue Reading
Li-Cycle Announces $15 Million Public Offering Insights

Updated Category News Views 213

Li-Cycle Announces $15 Million Underwritten Public Offering Li-Cycle Holdings Corp. (NYSE: LICY), a recognized leader in lithium-ion battery resource recovery, has unveiled details about its recent public offering. This strategically planned offering is projected to raise approximately $15 million for the company, providing essential funding to support its ongoing and...

Continue Reading
Investors Encouraged to Join Edwards Lifesciences Case

Updated Category News Views 117

Investors Encouraged to Join Edwards Lifesciences Case In recent developments, the Rosen Law Firm, a dedicated advocate for investor rights, is reaching out to individuals who purchased securities of Edwards Lifesciences Corporation (NYSE: EW) during a specified time frame. This outreach aims to inform these investors about their rights and potential avenues to seek...

Continue Reading
AtlasNova's $2.3M Funding to Transform Small Business Automation

Updated Category News Views 318

AtlasNova Secures $2.3 Million for Small Business Automation With the latest funding, AtlasNova is dedicated to enhancing the operations of small businesses, helping them leverage efficiencies that typically only larger corporations enjoy. Unlocking Potential Through Intelligent Automation AtlasNova has successfully secured a seed round of $2.3 million, enabling them to...

Continue Reading
Congressman Questions SEC's 'Digital Asset Security' Definition

Updated Category News Views 196

Congressman Ritchie Torres Questions SEC's Use of Terminology Representative Ritchie Torres, a Democratic representative from New York, has recently shared his concerns about the phrase "digital asset security" as used by the U.S. Securities and Exchange Commission (SEC). He’s particularly interested in the legal basis and origins of this term. Congressional Dialogue...

Continue Reading